Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Udomsak Udomnilobol"'
Autor:
Udomsak Udomnilobol, Wilasinee Dunkoksung, Watchara Sakares, Suree Jianmongkol, Thomayant Prueksaritanont
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Dabigatran etexilate (DABE) is a clinical probe substrate for studying drug-drug interaction (DDI) through an intestinal P-glycoprotein (P-gp). A recent in vitro study, however, has suggested a potentially significant involvement of CYP3A-mediated ox
Externí odkaz:
https://doaj.org/article/95f7abe01b0d4fe782a9783994c22379
Autor:
Nattiya Hirankarn, Trairak Pisitkun, Nonthaneth Nalinratana, Niphat Jirapongwattana, Udomsak Udomnilobol, Songkiat Songthammanuphap, Eakkaphon Rattanangkool, Nopparat Thavornsin, Sirikan Deesiri, Jakkrit Srisa, Jakapun Soponpong, Supanan Ampawa, Chayan Charoenpakdee, Wilasinee Dunkoksung, Tanachote Ruengsatra, Supranee Buranapraditkun, Tirayut Vilaivan, Thomayant Prueksaritanont
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/67ce0443e53248e29280baa9b4b0cfc0
Autor:
Punyabhorn Rattanacheeworn, Stephen J Kerr, Wonngarm Kittanamongkolchai, Natavudh Townamchai, Suwasin Udomkarnjananun, Kearkiat Praditpornsilpa, Thanundorn Thanusuwannasak, Udomsak Udomnilobol, Suree Jianmongkol, Boonsri Ongpipattanakul, Thomayant Prueksaritanont, Yingyos Avihingsanon, Pajaree Chariyavilaskul
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Ageing and chronic kidney disease (CKD) affect pharmacokinetic (PK) parameters. Since mechanisms are related and remain unclear, cytochrome P450 (CYP) 3A and drug transporter activities were investigated in the elderly with or without CKD
Externí odkaz:
https://doaj.org/article/009bc8b1a9aa4cf6889e73b639ea2bfb
Publikováno v:
Drug Metabolism and Disposition. :DMD-AR
Autor:
Nikunjkumar Patel, Arpar Ngampanya, Boonsri Ongpipattanakul, Suree Jianmongkol, Thomayant Prueksaritanont, Pakawadee Sermsappasuk, Udomsak Udomnilobol, Natapol Pornputtapong
Publikováno v:
Journal of pharmaceutical sciences. 110(5)
In this study, we aimed to develop and qualify a PBPK model for scalp application using two drugs with marked differences in physicochemical properties and PK profiles. The parameters related to scalp physiology, drug PK, and formulations were incorp